Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06141135
Recruiting Not applicable

GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial

NCT06141135 · tracked via the Priya Life Science USA tracker
Sponsor
Genomic Prediction Inc
Phase
Not applicable
Started
2023-11-15
Last updated
2025-08-26

Condition(s) studied

Infertility, Female

Investigational drug(s) / intervention(s)

Preimplantation genetic testing for aneuploidy (PGTA)

Preimplantation genetic testing for aneuploidy (PGTA): 24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)

Study summary

The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

Eligibility

Sex
FEMALE
Min age
35 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI (recommended) or ---Traditional IVF * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols Exclusion Criteria: * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers * Preimplantation genetic testing for monogenic/single gene disorders (PGT-M) * Translocation carriers

Primary outcome measure(s)

  • Ongoing Pregnancy Rate — Up to 2 years
    The number of participants who experience an ongoing clinical pregnancy rate after the 1st embryo transfer.

Trial sites (1)

FacilityCityRegionStatus
Boston IVF Waltham Massachusetts Recruiting

More Genomic Prediction Inc. trials in the USA

Cell Free Preimplantation Genetic Testing Starting soon
Follow-up With Preimplantation Genetic Testing Patients Recruiting
Preimplantation Genetic Testing in Women of Advanced Maternal Age Recruiting
ANXA5 M2 Haplotyping in IVF Patients and Embryos Active, not recruiting

Other trials for the same condition

Cell Free Preimplantation Genetic Testing Starting soon
Preimplantation Genetic Testing in Women of Advanced Maternal Age Recruiting
Embryo Assessment Utilizing Timelapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next Generation Sequencing Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06141135 on ClinicalTrials.gov ↗ ← All trials in the USA